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ABSTRACT
Since Brain-Derived Neurotrophic Factor’s (BDNF) discovery in 1982, we know
that it plays a critical role in both cell survival and cell death within the central nervous
system (CNS). It has been established that BDNF, serves as a regulatory body in the
CNS, from development to adulthood by promoting neuronal health, survival, and
maintenance. However, little is known about BDNF’s role in the pathogenesis of
neurological, neurodegenerative, and neuropsychiatric disorders. Therefore, in this study,
we used western blots analysis, to examine the effects of global BDNF knockdown on the
protein expression of multiple inflammasome and glial cell markers in healthy male and
female rat brains. We hypothesize that BDNF heterozygous rats (BDNF +/- KD), will have
altered protein expression of inflammatory markers due to BDNF loss, and that this may
occur in a sex specific manner. To test this hypothesis, we examined the activation of the
NLRP3 inflammasome pathway in male and female rat hippocampal tissue. When
compared to wildtype (WT) controls, only BDNF+/- KD males showed a significant
increased protein level expression of reactive oxygen species (TXNIP), and
inflammasome marker Caspase-1. When taken together, all four inflammasome markers
(NLRP3, ASC, Caspase-1, IL1-β) showed a visual pattern of increase only in the male
hippocampi (HPC) and not in the females after BDNF+/- KD. In conclusion our results
compel us to believe that BDNF reduction leads to priming of the inflammation in the brain
and not a full-blown inflammatory state. This is observed in a sex specific manner, with
effects seen only in the male HPC. These findings contribute information about BDNF’s
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involvement in neuroinflammation and will aid in the development of more effective
treatment options for neurodegenerative, and neuropsychiatric disorders in the future.
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CHAPTER ONE
OVERVIEW AND SPECIFIC AIMS
Statement of the Problem
In a healthy brain, BDNF serves as a regulatory body in the CNS from development
to adulthood by promoting neuronal health, survival, and maintenance (Kazak & Yarim,
2017; Numakawa et al., 2010). Previous studies, conducted on neurodegenerative and
neuropsychiatric disorders have indicated that, loss of BDNF protein expression leads
disrupted BDNF down-stream signaling. It has been determined through prior research,
deficits in down-stream synaptic signaling is the cause for many neurological disorders
(Boger et al., 2011; Dansokho & Heneka, 2018; Lima Giacobbo et al., 2019; Pillai, 2008).
A common symptom found among all these neurological disorders is BDNF reduction and
chronic neuroinflammation (Andero, Choi, & Ressler, 2014; Balaratnasingam & Janca,
2012; Dansokho & Heneka, 2018; Mortezaee, Khanlarkhani, Beyer, & Zendedel, 2018;
Russo-Neustadt, 2003). However, little is known about the molecular mechanisms of
BDNF and its role in neuroinflammation (Lai et al., 2018; Lamkanfi & Dixit, 2012). In order
to determine how BDNF loss affects neuroinflammation in the hippocampus we must look
at it under non-pathologic conditions and if there are any sex differences. We also must
examine what pathways that are affected specifically by neuroinflammation. In our study
we hypothesize that BDNF heterozygous rats (BDNF+/- KD) will have altered protein levels
of inflammatory markers due to reduction of BDNF expression, and that this may occur in
a sex specific manner. We will test this hypothesis through examination of inflammation
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within the Central Nervous System (CNS), specifically through examining the NLRP3
inflammasome pathway (NLRP3 pathway: ASC, Caspase1, and IL-1β).

Specific Aims
Aim 1: To understand the basal relationship between BDNF and how its neuronal
functioning affects neuroinflammatory pathways. To do this, we knocked down BDNF in
the rodent brain to determine if the reduction of BDNF induces activation of NLRP3
inflamamsome pathway proteins, namely, NLRP3, ASC, Caspase1, and IL-1β. This was
followed by measuring upstream oxidative stress marker, TXNIP and overall inflammation
by looking at glial cell activation.
Aim 2: To determine if sex differences play a role in BDNF regulation and
neuroinflammation. We used sex-matched groups to compare post-mortem hippocampal
tissue from male and female WT rat to BDNF+/- KD rats via western blot protein expression
of reactive oxygen species (TXNIP), the NLRP3 inflammasome pathway (NLRP3, ASC,
Caspase1, and IL-1β), and glial cell immune response (Iba1, and GFAP).
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CHAPTER TWO
INTRODUCTION AND LITERATURE REVIEW
Brain Derived Neurotrophic Factor (BDNF): An Introduction to the
Family of Neurotrophins
Sixty years ago the first neurotrophic factor was discovered, Nerve Growth Factor
(NGF)(Levi-Montalcini, 1964; Mitre, Mariga, & Chao, 2017). NGF was found to be a
secreted protein that was necessary for neuronal development and survival (Ceni,
Unsain, Zeinieh, & Barker, 2014). Preliminary studies discovered that NGF receptors are
expressed by peripheral neurons(Ceni et al., 2014; Dechant & Neumann, 2002). This
discovery of NGF led to the identification of other neurotrophic factors. The second
neurotrophin discovered was Brain derived neurotrophic factor (BDNF)(Russo-Neustadt,
2003). BDNF has been established as a major trophic factor within the central nervous
system (CNS) (D. Y. Liu et al., 2015). BDNF impacts multiple facets of neuronal function,
including growth, morphology, and synaptic plasticity (Gomez-Palacio-Schjetnan &
Escobar, 2013). When BDNF is absent neuronal function and plasticity decrease,
suggesting that BDNF integrates circuits and signaling pathways throughout the CNS
(Dechant & Neumann, 2002; D. Y. Liu et al., 2015; Mitre et al., 2017).
Previous research has shown that neurotrophins have a regulatory role in the
immune response within the CNS (Bothwell, 2016). Neurotrophins are protein growth
factors, are necessary for neuronal survival, differentiation, and maintenance from
development to adulthood (Bibel & Barde, 2000; Bothwell, 2014; Mitre et al., 2017). There
are four major neurotrophins: NGF, BDNF, NT-3, NT-4; all four trophins impact
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bidirectional signaling between the neurosensory network and immune cells (Barbacid,
1995; Bothwell, 2016; Manti, Brown, Perez, & Piedimonte, 2017).
What is unique about neurotrophins is that they are vital for CNS and PNS function
in their immature form, referred to as a proneurotrophins, and their mature form (Gibon &
Barker, 2017). Once the proneurotrophin is synthesized and is cleaved intercellularly as
well as extracellularly it transforms into its mature state (Mitre et al., 2017; Rafieva &
Gasanov, 2016). Both pro and mature neurotrophins have conflicting roles as they can
promote cell survival but also cell death, which is unique in the CNS (Dechant &
Neumann, 2002; Gibon & Barker, 2017; Twiss, Chang, & Schanen, 2006).
Neurotrophins provide support after any insult or injury within the CNS (Ceni et
al., 2014; Rafieva & Gasanov, 2016). A commonality found among all neurotrophins is
their ability to synthesis in cells as long precursors are present and contain a N-terminal
signal peptide and can follow the N-terminal signal (Bothwell, 2016; Mitre et al., 2017;
Rafieva & Gasanov, 2016). This is what has propelled us to further investigate BDNF’s
pathways and receptors in order to understand its cellular and molecular function within
the CNS and what happens when it is reduced or absent (Ceni et al., 2014; Khan & Smith,
2015; Skaper, 2008a, 2008b, 2012). BDNF is known to have a high affinity for binding to
neurotrophic tyrosine kinase (Trk) receptor, (Davies, 2008; Skaper, 2012; Teng, Felice,
Kim, & Hempstead, 2010) it has a low affinity for binding to pan neurotrophin receptor
(p75NTR) (Davies, Minichiello, & Klein, 1995; Patapoutian & Reichardt, 2001; F. Zhang,
Kang, Li, Xiao, & Zhou, 2012). This review will be focusing on BDNF mechanisms,
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function, receptors, neuro-pathobiology, clinical application and its role in CNS
inflammation. (Khan & Smith, 2015).
BDNF Function
The function of BDNF has previously been identified as promoting neuronal
survival, neuronal maintenance, and synaptic plasticity (Lima Giacobbo et al., 2019). As
indicated in the previous section, and it is known that BDNF is a member of the
neurotrophin family that serves as a regulatory body within the central nervous system
from development to adulthood (Lima Giacobbo et al., 2019). What has not been
mentioned is the cell biology of BDNF and what makes it a key regulator of cellular
cognition processing resulting in complex behaviors (Aid, Kazantseva, Piirsoo, Palm, &
Timmusk, 2007). When a BDNF knockout is created in a rodent model the animals only
live a few weeks and exhibit sensory impairments (Aid et al., 2007; Barker, 2009; Begni,
Riva, & Cattaneo, 2017) In our study we used a knockdown rodent model, to ensure that
our animals reached adulthood and so we could study BDNF loss (Ernfors, Lee, &
Jaenisch, 1994; Jones, Farinas, Backus, & Reichardt, 1994; Lima Giacobbo et al., 2019).
BDNF’s gene expression in humans has a complex structure that incorporates
multiple promoters, splice sites, and three UTR poly-adenylation sites, which results in a
sophisticated transcript regulation of messenger RNA (Aid et al., 2007; Barde, Edgar, &
Thoenen, 1982; Begni et al., 2017; Boulle et al., 2012; Martinez-Levy & Cruz-Fuentes,
2014). The cellular role of the RNA transcripts plays an important role in the epigenetic
modification of the regulation of the BDNF gene transcription (Aid et al., 2007; Barker,
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2009; Lima Giacobbo et al., 2019; Marini et al., 2004; Pruunsild, Kazantseva, Aid, Palm,
& Timmusk, 2007).
To fully understand the function of BDNF, the gene’s composition and expression
must be understood (Boulle et al., 2012; Marini et al., 2004). The BDNF gene is composed
of a common 3′-exon which encodes the immature form of BDNF called pro-BDNF protein
(Martinez-Levy & Cruz-Fuentes, 2014), and is followed by multiple species dependent 5′noncoding, promoter-regulated regions, and ending in a coding 5′-noncoding (Aid et al.,
2007; Barker, 2009; Begni et al., 2017; Lima Giacobbo et al., 2019; Pruunsild et al., 2007).
The gene’s expression is regulated by a wide range of endogenous and exogenous
stimuli, including chronic stress (Lupien, McEwen, Gunnar, & Heim, 2009; McEwen,
2012). The BDNF gene transcribes pro-BDNF, which is then cleaved into BDNF in the
cytoplasm by the extracellular matrix or the endoprotease (Barker, 2009; Lima Giacobbo
et al., 2019; Lu, Pang, & Woo, 2005).
BDNF acts on two independent receptors within the brain responsible for
physiological brain functions (Borodinova & Salozhin, 2016). A complex system of
downstream signaling cascades effecting both pro and mature BDNF through two major
receptors: tropomyosin-related kinase B (TrkB) and pan 75 neurotrophin receptor
(p75NTR) (Borodinova & Salozhin, 2016; Lu et al., 2005; Minichiello, 2009). BDNF and
pro-BDNF will bind with a low affinity to p75NTR. When BDNF binds to p75NTR it starts
a cascade activation of apoptosis (the cell death cascade) within the CNS (BernardGauthier, Boudjemeline, Rosa-Neto, Thiel, & Schirrmacher, 2013). However, when
mature BDNF binds to its high affinity receptor TrkB, numerous intracellular signaling
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pathways become active including protein kinases pathways (MAPK, ERK, PI3K)
pathways (Bernard-Gauthier et al., 2013; Lu et al., 2005; Minichiello, 2009). BDNF/TrkBstimulated intracellular signaling is a major component of synaptic plasticity, neuronal
survival and morphogenesis (Numakawa, Suzuki et al. 2010(Lima Giacobbo et al.,
2019)). Additional studies, (including this study) are now being conducted to determine
how deficiencies in BDNF contribute to the pathogenesis of several neurological
diseases: sleep disorders, psychiatric disorders, Huntington Disease, Parkinson’s
disease, and Alzheimer’s disease (Lima Giacobbo et al., 2019; Lu, Nagappan, Guan,
Nathan, & Wren, 2013).
BDNF Signal Transduction
BDNF’s directly impacts transcription, processing, and secretion are regulated by
synaptic activity (Leal, Bramham, & Duarte, 2017). Since, BDNF’s major role in the CNS
is to sustain an enhancement of activity dependent synaptic activity within in the
hippocampus promoting learning and memory (Kojima & Mizui, 2017; Kowianski et al.,
2018)..Both experimental and clinical trials have shown that stress and depression
decrease BDNF expression throughout the brain (Aid et al., 2007; Kozisek, Middlemas,
& Bylund, 2008; Lupien et al., 2009; McEwen, 2012). The decrease in BDNF expression
reduces neurogenesis; however, treatment with an antidepressant aim to reverse the
effects of reduced BDNF expression (Kozisek et al., 2008; McEwen, 2012). Research
suggests that stress both in childhood and adulthood can lead to structural changes in
the brain. These structural changes result in the impairment of memory formation by
blocking information acquisition in the neuronal networks that modulate mood (Kozisek
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et al., 2008; Lima Giacobbo et al., 2019; Lupien et al., 2009; McEwen, 2012; Minichiello,
2009).
BDNF is a regulator of synaptic transmission, which is a key component of LTP in
the hippocampus. The hippocampus is the brain region that is an integral part of the
memory formation loop (Leal et al., 2017). Thus, understanding the effect BDNF has on
LTP is necessary and in order to study BDNF the TrkB receptor, which is the receptor
BDNF binds to, needs to be understood (Lu et al., 2005; Minichiello, 2009). BDNF’s role
in LTP has been most extensively studied in the hippocampus where it acts on both the
pre and post synapse(Leal, Comprido, & Duarte, 2014). BDNF regulates mRNA
transportation along the dendrites by acting during the translation phase within the
synapse (Leal et al., 2014). BDNF does this through modulating the beginning of the
elongation phase during protein synthesis by acting on specific microRNA (miRNA) (Leal
et al., 2014). The transcription regulation that BDNF affects is believed to be one of the
mechanisms involved in both short and long-term regulation of the synaptic proteome and
how it effects synaptic plasticity (Leal, Afonso, Salazar, & Duarte, 2015; Leal et al., 2017;
Leal et al., 2014; Lu, Nagappan, & Lu, 2014).The molecular mechanisms that BDNF
activates triggering LTP are the TrkB receptor, rescue of L-LTP when protein synthesis is
blocked, BDFN/TrkB regulation of dendritic spines (Nibuya, Morinobu, & Duman, 1995).
These three mechanisms affect different forms of LTP in the hippocampus (Panja and
Bramham 2014).
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Neuropathology and BDNF
Neurodegenerative Disorders and BDNF
Everyday there are estimates of hundreds of millions of people around the world
that are diagnosed with a neurological disorder. It is estimated that 47.5 million people
worldwide are affected by dementia with the commonality of Alzheimer’s Disease being
the cause. The stark reality is that approximately 7.7 million new cases each year emerge
with

a

neurodegenerative

disorder’s

diagnosis

(WHO,

2016;

[http://www.who.int/features/qa/55/en/]) (Tejeda & Diaz-Guerra, 2017). Despite much
research the etiology of these diseases, there is still so much that researchers do not
know. The most glaring problem is understanding the disease’s onset and progression
(Lima Giacobbo et al., 2019). Similar to neurological disorders, neurodegenerative
disorders also have been reported to have low BDNF levels followed by chronic
neuroinflammation (ex: Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s
Disease is neuroinflammation) (Hashimoto et al., 2005; Lu et al., 2013; Yuan et al., 2010)
The molecular mechanisms of how BDNF at an excitatory synapse activates TrkB
receptors effecting downstream signaling pathways (Hempstead, 2015; Leal et al., 2017).
Our current treatment plans for these disorders rely on restricting the aversive symptoms,
which is not curative (Michalski, Corrada, Kawas, & Fahnestock, 2015; Qin et al., 2017).
While, cognitive testing and neuroimaging have provided doctors and researchers greater
understanding of the progression of the diseases, they are still not able to detect the
neurodegeneration in its earliest stages (Agrawal & Biswas, 2015; L. L. Wu, Fan, Li, Li, &
Zhou, 2010; Zuccato & Cattaneo, 2014). Only after a catastrophic cascade of damage
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has taken place are doctors able to resolutely diagnosis the disease(Fenner, Achim, &
Fenner, 2014; Parain et al., 1999; Porritt, Batchelor, & Howells, 2005; Tejeda & DiazGuerra, 2017). Since the discovery of biomarkers, there has been a push to use them to
aid in the early stage diagnosis of neurodegenerative disorders (Agrawal & Biswas, 2015;
Jove, Portero-Otin, Naudi, Ferrer, & Pamplona, 2014; L. L. Wu et al., 2010; Zuccato &
Cattaneo, 2014). BDNF is being considered as a biomarker for early detection diagnosis
(Agrawal & Biswas, 2015; Barthel, Schroeter, Hoffmann, & Sabri, 2015; Jove et al., 2014;
Lima Giacobbo et al., 2019; Parnetti et al., 2013; Zhu, Ploessl, & Kung, 2014).
A majority of neurological disorders display either BDNF dysregulation or loss of
BDNF leading to impairment of the BDNF signaling pathway (Tejeda & Diaz-Guerra,
2017). BDNF/TrkB signaling in cell function plays a key role in the stability of the central
nervous system, and subtle changes in expression or downstream signaling can have
dire consequences such as neurological and psychiatric disorders (Michalski et al., 2015).
In Alzheimer’s Disease (AD) neurotrophic signaling is impaired, and excitotoxicity results
in neuronal death, this patterns found in multiple progressive neurodegenerative
disorders (Qin et al., 2017; Tejeda & Diaz-Guerra, 2017)..
Patients with AD have neurotrophic signaling impairment, excitotoxicity results in
neuronal death, and this pattern is found in multiple progressive neurodegenerative
disorders (Qin et al., 2017; Selkoe, 2002). Individuals with AD have a progressive
decrease of synapses and neurons within the hippocampus and cortex, resulting in short
term memory loss (Braak & Braak, 1991; Masliah et al., 1994). AD is identified by the
development of senile plaques, which are comprised of extracellular deposits of misfolded
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amyloid β-peptide (Aβ) and intracellular neurofibrillary tangles (Elliott, Atlas, Lange, &
Ginzburg, 2005; Peng, Wuu, Mufson, & Fahnestock, 2005). BDNF levels are reduced in
individuals with AD when compared to healthy patients which is believed to be a crucial
factor in cognitive decline since mature BDNF promotes neuronal function (Michalski et
al., 2015; Qin et al., 2017).
Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disorder
initiated by CAG expansion of the huntingtin (Htt) gene, creating a faulty elongation of the
polyglutamine (polyQ) tract at the Htt N-terminus (Tejeda & Diaz-Guerra, 2017; Zuccato
& Cattaneo, 2014). This dysfunction or cell death of medium sized spiny neurons (MSNs)
located within the striatum is the main symptom of disease onset. Through the
progression of HD, MSNs are monitored (Zuccato & Cattaneo, 2014). MSN declines are
characterized by motor, cognitive decline, and psychiatric decline (Ferrer, Goutan, Marin,
Rey, & Ribalta, 2000). Like with AD individuals diagnosed with HD often have BDNF loss
in their symptomatic stages (Ferrer et al., 2000). Notably, it has been indicated that a
reduction of BDNF/TrkB signaling might be the cause for the susceptibility of MSNs in HD
patients (Tejeda & Diaz-Guerra, 2017; Zuccato & Cattaneo, 2014; Zuccato et al., 2001).
HD patients, additionally, have global reduction of neurotrophin expression throughout
the brain that inhibits corticostriatal transportation (Ferrer et al., 2000; Gauthier et al.,
2004; Zuccato & Cattaneo, 2014; Zuccato et al., 2001). This presents a unique problem
within the CNS since a majority of BDNF within the striatum is synthesized and delivered
anterogradely via cells from the cerebral cortex (Altar & DiStefano, 1998). Bizarrely, wild
type Htt is a component of the motor complex that moves BDNF vesicles down
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microtubules of the cell (Gauthier et al., 2004). When the polyQ tract becomes enlarged
its causes the mutant Htt gene to overwhelm the complex, inhibiting the vesicle’s
movement creating a strengthen bond to Htt-associated protein 1 resulting in disease
onset ((Altar & DiStefano, 1998)Gauthier et al., 2004). The disease onset if followed by a
reduced expression of pro-BDNF, inhibiting proBDNF’s apoptotic function (L. L. Wu et al.,
2010; Zuccato & Cattaneo, 2014). When all these events co-occur, individuals with HD
have a deficit in their ability to enlist motor proteins to microtubules, drastically reducing
neurotrophin release and transportation(Dompierre et al., 2007; Engelender et al., 1997;
Ferrer et al., 2000). Individuals with HD have a reduction of neurotrophic support and
receptor availability disrupting the balance of Trkb signaling in the Striatum leading to
cognitive and motor movement deficits (106-110)(Tejeda & Diaz-Guerra, 2017; Zuccato
& Cattaneo, 2014; Zuccato et al., 2001).
Parkinson’s Disease (PD) is one of the most prevalent movement disorders (Boger
et al., 2011), its onset presents with a reduction/loss of dopaminergic neurons in the
substantia nigra pars compacta (SNpc), and inhibited intracellular gathering of αsynuclein inclusions (also referred to as (Lewy bodies & Lewy neurites) (Parain et al.,
1999; Porritt et al., 2005; Tejeda & Diaz-Guerra, 2017). Through postmortem analysis,
individuals suffering from PD show a reduction of both BDNF mRNA and protein in the
SNpc and Striatum (Benisty, Boissiere, Faucheux, Agid, & Hirsch, 1998; Howells et al.,
2000; Miller et al., 2006; Parain et al., 1999; Porritt et al., 2005). When further analyzed
at a structural and protein level, the changes found in the surviving neurons located in
SNpc are small in PD patients (Mohammadi, Amooeian, & Rashidi, 2018; Tejeda & Diaz12

Guerra, 2017). However, this small protein change leads to an impairment of neurotrophin
signaling to the TrkB receptor (Fenner et al., 2014; Tejeda & Diaz-Guerra, 2017). The
subcellular distribution of TrkB-FL and TrkB-T1 in the disease progression of PD reduces
catalytic receptor isoform within the dendrites inhibiting synaptic function (Ding et al.,
2011; Hung & Lee, 1996). BDNF/TrkB signaling loss in the substantia nigra (SN) is
particularly devastating because it increases the risk of dopaminergic cytotoxicity is
believed to contribute to the onset and progression of PD (Benisty et al., 1998; Ding et
al., 2011; von Bohlen und Halbach, Minichiello, & Unsicker, 2005). When examined in
animal models reduction or loss of BDNF expression or downstream signaling through
the TrkB receptor has shown motor dysfunction and loss in aged animals (Boger et al.,
2011). Indicating that, BDNF loss can cause dopaminergic neuron loss in the SN in aged
animals (Baydyuk, Nguyen, & Xu, 2011; Boger et al., 2011; Porritt et al., 2005; Tejeda &
Diaz-Guerra, 2017; von Bohlen und Halbach et al., 2005).
Neuropsychiatric Disorders and BDNF
The pathophysiology of multiple psychiatric disorders appears linked to impairment
of BDNF/TrkB signaling and expression (Tejeda & Diaz-Guerra, 2017). One of the most
studied psychiatric disorders is depression (Benatti et al., 2016). Depression in the brain
is the inability to employ adaptive plasticity through neurotrophic signaling in the
hippocampus, and cerebral cortex (Nestler et al., 2002). Numerous studies have
supported the claim that neurotrophins play a critical role in depression (Benatti et al.,
2016; Krishnan & Nestler, 2010; Nestler et al., 2002). Patients who seek antidepressant
treatment for chronic depression have increased BDNF in their blood posttreatment
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(Brunoni, Lopes, & Fregni, 2008; Sen, Duman, & Sanacora, 2008). The mechanism of
many antidepressants is it to increase the expression of TrkB mRNA inducing a state of
rapid activation for the TrkB receptor (Nibuya et al., 1995; Rantamaki et al., 2007; J. C.
Zhang, Yao, & Hashimoto, 2016). This rapid activation or the TrkB receptor plays a critical
role in the efficacy of antidepressants that rely on the expression and signaling of the
BDNF/TrkB pathway (Duman & Monteggia, 2006; Nestler et al., 2002; Rantamaki et al.,
2007; J. C. Zhang et al., 2016). When BDNF is used as an antidepressant treatment, it
has been reported to have the same therapeutic effects as antidepressants in animal
models (Siuciak, Lewis, Wiegand, & Lindsay, 1997).
Atypical neurotrophin expression is a major symptom in the pathogenesis of
Schizophrenia. Individuals with schizophrenia suffer from cognition and perception
impairments (Tejeda & Diaz-Guerra, 2017), and have decreases in dendritic spines and
synaptic plasticity (Chen et al., 2009; Glausier & Lewis, 2013; Siuciak et al., 1997).
Multiple studies have demonstrated that patients with schizophrenia have reduced levels
of BDNF(Chen et al., 2009). Additionally, patients with schizophrenia have changes in the
BDNF protein and total mRNA located within the prefrontal cortex (Durany et al., 2001;
Hashimoto et al., 2005; Weickert et al., 2003). BDNF regulation maybe altered through
irregular DNA methylation, specifically at the growth arrest and DNA-damage-inducible β
protein (GADD45b) (Gavin et al., 2012). GADD45b is a promoter that is diminished in
patients with schizophrenia(Gavin et al., 2012). When patients have reduced levels of
GADD45b and decreased TrkB mRNA and BDNF protein expression, the downstream
signaling is severely diminished in the prefrontal cortex (Emamian, Hall, Birnbaum,
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Karayiorgou, & Gogos, 2004; Hashimoto et al., 2005; Weickert et al., 2003; Yuan et al.,
2010).
Epilepsy is viewed as steaming from abnormal neuronal excitability, resulting from
exorbitant activation of TrkB-FL (G. Liu et al., 2013). For epilepsy to manifest, atypical
TrkB signaling must occur through the PLCγ pathway (Gu et al., 2015). Because epilepsy
is characterized by recurrent seizures, it can cause molecular changes in neuron and glial
cell expression of the glutamate receptors and uptake transporters causing excitotoxicity,
resulting in permanent brain damage (Barker-Haliski & White, 2015; Tejeda & DiazGuerra, 2017). In Vitro models of epilepsy illustrated that when BDNF expression is not
appropriately regulated within the CNS, all downstream signaling is interrupted and
negatively impacted (Danelon, Montroull, Unsain, Barker, & Masco, 2016; Xie et al.,
2014). As indicated above, many neuropsychiatric disorders are caused by an abnormal
regulation of BDNF/TrkB signaling. Ironically if this abnormality is corrected, BDNF could
be consider to be a therapeutic treatment (Tejeda & Diaz-Guerra, 2017). More research
is needed to examine the possibilities of restoring neurotrophic signaling (Tejeda & DiazGuerra, 2017). Restoration of just the BDNF/TrkB signaling pathway could lead to an
increase in adult neurogenesis, increase synaptic plasticity, and serve as neuroprotection
(Lu et al., 2013; Xie et al., 2014).
Stroke and BDNF
Stroke is one of the top five deadliest diseases in the United States, caused by a
lack of blood flow to the brain usually caused by a blood clot or burst blood vessel,
resulting in oxygen deprivation to the brain causing tissue damage (Guzik & Bushnell,
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2017). Post, stroke recovery is a challenging road for many patients whom have lost motor
function and is considered a long-term disability(Jorgensen et al., 1995). For stroke
patients to regain motor function and motor skills neuroplasticity is required (Mang,
Campbell, Ross, & Boyd, 2013). Current research is focused on promoting neuroplasticity
in poststroke patients by optimizing BDNF expression (Mang et al., 2013).
As a result of lack of pharmacologic interventions and treatments for patients
recovering from stroke, there is a continuous search into discovering novel treatment
options for the long-term disability associated with stroke recovery (Berretta, Tzeng, &
Clarkson, 2014). It is known that BDNF and its TrkB receptor are synthesized and
expressed throughout the brain regulating neuronal activity. Recently, BDNF has been
shown to be neuroprotective and aid in recovery of motor skills/function poststroke(Berretta et al., 2014).
BDNF promotes neuroplasticity, neurogenesis, and is involved in neuroprotection
(Mang et al., 2013). BDNF is essential for stroke victims to relearn and regain motor
control throughout their recovery (Mang et al., 2013). Current stroke rehabilitation utilizes
aerobic exercise to upregulate BDNF expression throughout the central nervous system
(Cotman, Berchtold, & Christie, 2007; Kluding, Tseng, & Billinger, 2011; Kramer,
Erickson, & Colcombe, 2006; Lambourne & Tomporowski, 2010; Rand, Eng, LiuAmbrose, & Tawashy, 2010). Aerobic exercise would naturally increase BDNF expression
and aid motor learning through promoting neuroplasticity in stroke victims (Cotman &
Berchtold, 2002; Cotman et al., 2007; Knaepen, Goekint, Heyman, & Meeusen, 2010).
However, aerobic exercise alone does not promote neuroplasticity. Exercise creates a
16

conducive environment that will support neuroplasticity, which in many cases is the first
step towards recovery and motor rehabilitation (Kleim, Cooper, & VandenBerg, 2002;
Mang et al., 2013).
Traumatic Brain Injury and BDNF
Traumatic Brain Injury (TBI) has become a worldwide cause of death/disability for
teenagers, adults, and the elderly (Bruns & Hauser, 2003; da Silva Meirelles, Simon, &
Regner, 2017; Fleminger & Ponsford, 2005; Leibson et al., 2011). It is estimated that
around 10 million people worldwide are annually affected by TBIs (Chauhan, 2014).
Patients suffering from a severe TBI have a 50% mortality rate that is unfortunately due
to the lack or restorative treatment options (Hyder, Wunderlich, Puvanachandra, Gururaj,
& Kobusingye, 2007; McDonald, Sun, Agoston, & Shultz, 2016). A majority of TBIs are
associated with a loss of homeostasis within the CNS caused by external trauma (Bruns
& Hauser, 2003; Fleminger & Ponsford, 2005). External trauma in this instance is any
insult or injury to the brain resulting in damage of brain tissue (McKee & Daneshvar, 2015;
Thakkar et al., 2016).
TBIs occur in two phases. The primary phase is the external insult and is identified
with temporary symptoms: damage to vasculature, axons, neurons, and glial cells (Stoica
& Faden, 2010; Wurzelmann, Romeika, & Sun, 2017). The secondary phase also referred
to as the second injury is after the immediate death of cells, causing a cascade of
biochemical changes around the primary injury (Stoica & Faden, 2010; Wurzelmann et
al., 2017). The biochemical cascade leads to further loss of neural tissue and function
(Stoica & Faden, 2010; Wurzelmann et al., 2017). Unfortunately, there is no
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pharmacologic intervention that will restore or rescue damaged neural tissue. A majority
of treatment options for TBI are symptomatic focused, with the goal of either
neurodegeneration or neuroprotection (Wurzelmann et al., 2017).
To determine the severity of the TBI in patients, clinicians use different metrics.
One of the most widely used scales for diagnosis is the three-tiered classification system
called the Glasgow Coma Scale (GSC). The GSC allows clinicians to rate the injury as
mild, moderate, or severe (Chieregato et al., 2010). TBI recovery today is dependent upon
multiple factors: age, GCS score, and pupillary response (McDonald et al., 2016).
BDNF’s role before a TBI is to promotes cell survival, cell growth, plasticity, and
long-term memory (Lorente, 2017). Out of all four neurotrophins BDNF is expressed more
than the others in humans (McAllister, Katz, & Lo, 1999). Studies on BDNF expression
post-TBI have delineated that the protein has a role in the pathophysiology of trauma, but
its exact role is disputed. There are studies that have indicated that BDNF is
neuroprotective (Kim & Zhao, 2005; Oyesiku et al., 1999; H. Wu et al., 2008) and other
studies that report it is neurodegenerative (Felderhoff-Mueser et al., 2002; Shetty, Rao,
Hattiangady, Zaman, & Shetty, 2004). Clinical trials also reported contradictory results;
some studies reported that patients had higher levels of BDNF post-TBI than the controls
while others reported lower levels of BDNF post TBI (Failla, Conley, & Wagner, 2016;
Korley et al., 2016). These conflicting results could be because a majority of clinical
studies did not determine if they were measuring the immature proBDNF form or the
Mature BDNF form (Koshimizu, Hazama, Hara, Ogura, & Kojima, 2010). BDNF in its
mature form is neuroprotective while proBDNF is neurodegerenative (da Silva Meirelles
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et al., 2017). Further research into the crucial role BDNF plays for the brain’s homeostasis
is needed in order to increase its efficacy as a possible treatment option for post TBI
recovery (da Silva Meirelles et al., 2017).

Neuroinflammation
The Role of BDNF and Neuroinflammation
BDNF is one of the most extensively studied neurotrophins in both healthy and
disease models due to its pathophysiology that is ubiquitous with numerous neurological
disorders (Lima Giacobbo et al., 2019). With the rise of neurological disorders worldwide,
there is a need for the development of more novel treatments as well as a further
understanding of the etiology of neurologic disorders (Whiteford et al., 2013). Since
numerous neurological disorders are caused by environmental factors it is important to
study outside factors as well (Lupien et al., 2009; Whiteford et al., 2013). Stress, for
example, is an environmental factor that is well known to initiate a cascade of health
problem. Stress is associated with stroke, heart attack, cognitive impairment,
metabolomic, mood, and endocrine changes (Lupien et al., 2009). Stress can wreak
havoc on the body and the brain, and chronic stress can activate pro-inflammatory glial
cells in the central nervous system that creates a pro-inflammatory environment within
the brain (McEwen, 2012). To combat the pro-inflammatory environment, antiinflammatory cytokines, glial cells, and neurotrophic factors are released to promote
neuronal survival within the brain (Thakkar et al., 2016). Subsequently, neurotrophic
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factors are known to promote neuronal survival (Lima Giacobbo et al., 2019; McEwen,
2012).
After any injury or insult in the central nervous system, inflammatory signals are
triggered causing multiple cascades signals throughout the cell leading to structural and
molecular changes (Lima Giacobbo et al., 2019). Two types of neuroinflammation occur
within the brain: pro-inflammatory and anti-inflammatory, and unfortunately both can
result in apoptosis (cell death) (Marini et al., 2004). Glial cells act as the brain’s immune
system response, particularly microglia and astrocytes that play a key role in the
pathological onset of the inflammatory process. Microglia release pro-inflammatory
cytokines, increasing the chances for neurotoxicity (Marini et al., 2004). As long as the
inflammatory signal is present, it can cause numerous neurological consequences such
as cognitive impairment and neurological and psychiatric disorders (Lima Giacobbo et al.,
2019; Marini et al., 2004; Oeckinghaus & Ghosh, 2009; Tilstra, Clauson, Niedernhofer, &
Robbins, 2011).
Thus, neurological disorders that have down regulation of BDNF release or loss,
in general, have caused many researchers to search for a link between
neuroinflammation and BDNF expression in the central nervous system (Lai et al., 2018;
Lamkanfi & Dixit, 2012; C. L. Wu, Hwang, Chen, Yin, & Yang, 2010). Since
neuroinflammation is a key part of onset/progression of a neurological disorder, our study
aims to add information on what happens when BDNF loss in a naïve animal occurs. Will
the BDNF loss prime the brain for neuroinflammation? If BDNF loss primes the activation
of oxidative stress (TXNIP), the NLRP3 pathway will activate, resulting in a
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neuroinflammatory response inside the cells within the brain (Lima Giacobbo et al., 2019;
Mangan et al., 2018; Xu et al., 2018).
NLRP3 Inflammasome Pathway
The inflammasome was first discovered in 2002 by Dr. Jurg Tschopp at the
university of Lausanne (Martinon, Burns, & Tschopp, 2002). The discovery of the
inflammasome revealed that inflammasomes are multiprotein complexes, they have
cytoplasmic localizations, and when activated form the inflammasome complex (Guarda
et al., 2011; Petrilli et al., 2007). When activation of the NLRP3 pathway occurs when the
cell receives a distress signal triggering the oligomerization of the inflammasome pathway
(Jo, Kim, Shin, & Sasakawa, 2016; Martinon et al., 2002). Once the inflammasome
pathway is constructed it releases cytokines, resulting in a proinflammatory response
within the brain (Petrilli et al., 2007).
When inflammation occurs in the brain it sends out signals that trigger the cytosolic
innate immune signaling receptor NLRP3 (Mangan et al., 2018). Once triggered, a
cascade of activation happens within the NLRP3 pathway (Hornung & Latz, 2010;
Lamkanfi, 2011). Following activation, recruitment of the adapter apoptosis-associated
speck-like protein containing a C-terminal caspase recruitment domain (ASC) occurs
(Davis, Wen, & Ting, 2011; De Nardo & Latz, 2011; Jo et al., 2016). When ASC is
activated it causes another chain link reaction by causing pro-caspase-1 to cleave into its
active form Caspase-1 (Jo et al., 2016). Caspase 1 then leads to the maturation of two
proinflammatory interleukin (IL)-1 family cytokines: IL-1β and IL-18 (Davis et al., 2011; De
Nardo & Latz, 2011; Lamkanfi, 2011; Martinon et al., 2002). The result is an inflammatory
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response with the release of active cytokines in the brain causing pyroptosis (De Nardo
& Latz, 2011; Jo et al., 2016; Lamkanfi, 2011).
Research on the molecular mechanisms involved in the activation of the NLRP3
pathway reveals believe that it occurs in two ways: transcription and post-translation(Jo
et al., 2016). To fully initiate the NLRP3 inflammasome pathway, a multiple protein
complex must be assembled through the binding of ASC, and pro-caspase-1 resuls in an
active inflammatory complex (Perregaux & Gabel, 1994; Petrilli et al., 2007). Only a few
molecule mechanisms have been proposed to induce the activation of the NLRP3
pathway: potassium efflux, lysosomal destabilization/rupture, and mitochondrial reactive
oxygen species (ROS) generation (Gurung, Lukens, & Kanneganti, 2015; Heid et al.,
2013; Jo et al., 2016; Okada, Matsuzawa, Yoshimura, & Ichijo, 2014; Perregaux & Gabel,
1994; Petrilli et al., 2007). Studies have shown that anomalous activation of the NLRP3
inflammasome pathway is connected to the pathogenesis of inflammation in
neurodegenerative disorders, psychiatric disorders, and stroke (De Nardo & Latz, 2011;
Lamkanfi, 2011). Further research is needed to develop targeted pharmacological
interventions to mitigate the damages of NLRP3 activation (Jo et al., 2016; Lamkanfi,
2011; Martinon et al., 2002; Petrilli et al., 2007).
Glial Cells
As stated in the previous section, microglia are the brain’s resident immune cells.
Microglia are charged with maintaining the brain’s tissue development, homeostasis, and
response to injury and repair. Microglia can adopt a wide range of phenotypes depending
on the function they need to preform to maintain homeostasis (Orihuela, McPherson, &
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Harry, 2016). Microglia originate around mid-embryonic development from primitive yolk
sac myeloid progenitors (Alliot, Godin, & Pessac, 1999; Ginhoux et al., 2010). As a result
of microglia’s pivotal role in the brain, it accounts for 10-15% of the brain’s total cell
population (Carson, Doose, Melchior, Schmid, & Ploix, 2006).
When the brain is in a normal state (e.g., no insult or injury present), microglia
maintain in their resting shape; this state resting state allows microglia to consistently
monitor the brain’s homeostasis (Davalos et al., 2005; Orihuela et al., 2016; Schmid et
al., 2009). Microglia can induce an immune response when pathogens are present and
maintain the brain’s homeostasis by clearing up debris, atypical proteins, and pyroptosis
(Carson et al., 2006; Fogg et al., 2006; Gautier et al., 2012; Paolicelli et al., 2011;
Parwaresch & Wacker, 1984). The microglia can be stimulated into two phenotype
polarizations, commonly referred to as M1 phenotype and M2 phenotype (Hu et al., 2012;
Orihuela et al., 2016). Microglia M1 phenotype can be activated via ligands LPS or IFN‐
γ, causing the expression of proinflammatory cytokines (Olah, Biber, Vinet, & Boddeke,
2011). The microglia M2 phenotype can be initiated to commence tissue repair and
combat inflammation in an anti-inflammatory capacity (Hu et al., 2012; Olah et al., 2011;
Orihuela et al., 2016; Patterson, 2015).
Another glial cell type that is a part of the central nervous systems immune
response are astrocytes. Within a healthy brain, astrocytes help maintain the brain’s
homeostasis by supporting neuronal function though sheer volume. Astrocytes make up
a majority of the cells found within the brain (Abbott, Ronnback, & Hansson, 2006). Since
the turn of the century, more research has been conducted into the functional role of
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astrocytes in the CNS, such as, neuronal support and synaptic transmission (Sofroniew
& Vinters, 2010). When an insult or injury occurs, astrocytes activate through a process
called reactive astrogliosis (Sofroniew & Vinters, 2010). When reactive astrogliosis is
present it indicates that damaged tissue is present, which can be caused by traumatic
lesions or neurological diseases (Abbott et al., 2006; Acosta, Gioia, & Silva, 2006; Akaoka
et al., 2001).
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CHAPTER THREE
MATERIALS AND METHODS
Animals
Young adult male (n = 9) and female (n = 9) Sprague Dawley rats were used for
this study. The rats were housed individually in a home cage with free access to food and
water. BDNF+/- heterozygous knockout rats had a seven base pair deletion in the BDNF
gene. Animals were divided into groups by sex and strain: WT females (n = 5), WT males
(n = 5), BDNF KD females (n = 4), and BDNF KO males (n = 4) (SAGE Labs, Boyertown,
PA). All the female animals used for this study underwent random estrous cycling that
was not monitored. All procedures were performed in accordance with the NIH Guidelines
for the Care and Use of Laboratory Animals at the University of Tennessee.

Tissue Harvest
Animals were euthanized using isoflurane overdose. Animals were decapitated
and the brains were removed for dissection. Individual brains were cut at the midsagittal
plane and the hippocampus from each hemisphere was dissected out. Hippocampal
tissues were stored at -20°C and homogenized for protein detection via Western blot
analysis.

Tissue Lysis
Hippocampal tissue was homogenized using RIPA buffer (Teknova). Tissue
suspended in RIPA buffer was subjected to sonication power of 2 until the tissue was
visibly solubilized in the buffer. The homogenized tissue was then allowed to rest on ice
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for 1 min. The homogenate was centrifuged at 12,000 rpm for 10 minutes. Supernatant
was collected in fresh tubes and used for further protein analyses.

Protein Estimation
The bicinchoninic acid method (BCA Protein Assay Kit, Thermo Scientific) was
used for quantification of total protein in each sample. Protein estimation was performed
using the 96-well plate method, as per the instructions of the kit. Bovine Serum Albumin
(BSA) was used as the standard. Absorbance was measured at 562 nm using a Biotek
plate reader and the protein concentration was calculated using the Gene5 software.

Western Blotting
The samples for western blotting were prepared by mixing 1X Laemmli buffer
(BioRad) with tissue homogenate and incubating in a water bath at 100oC for 10 min.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed
by loading the samples on 4-20% precast gels (BioRad). Protein samples were then
transferred on 0.45 µm nitrocellulose membrane (80V for 90 min) and blocked using 5%
BSA for 1 hour at room temperature on a shaker. The blots were then incubated with
primary antibody (Table 3.1) overnight at 4°C on a shaker. After the primary antibody
incubation, blots were washed with 1X TBST (10 min X 3) and incubated with the
respective HRP-conjugated secondary antibody. Following this, blots were washed,
developed using ECL (Clarity Western ECL substrate, BioRad) and scanned using
chemiluminescence on (Chemidoc Touch Imaging System, BioRad).

26

Table 3.1. Primary Antibodies used for Western Blotting
Primary Antibody
Catalog Number
BDNF
OSB00017W
IBA-1
Ab5076
GFAP
Ab7260
GAP DH
Ab8245
ASC
NBP1-78977
Caspase-1
NBP1-45433
NLRP3
NBP2-12446
IL-1-Beta
NB600-633
Beta-Actin
MAB8929
Vinculin
MCA465GA
NeuN
MAB377
TXNIP
14715S

Company
ThermoFisher Scientific
AbCam
AbCam
AbCam
NovusBio
NovusBio
NovusBio
NovusBio
R&D Systems
BioRad
Millipore
Cell Signaling Technologies

Quantification of Proteins
Blots were quantified using ImageJ software downloaded from NIH.gov. The band
intensity was measured and corrected for the corresponding housekeeping values. Data
are presented as average fold change of each group. Error bars indicate positive standard
error of the mean.

Statistical Analysis
Multiple t tests were used to compare significance between sex matched groups;
WT males compared to BDNF KD males; WT females compared to BDNF KD females.
Statistical significance was determined using the Bonferroni-Dunn method, with alpha set
to 0.05. Analyses were performed using PRISM software (version 7).
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CHAPTER FOUR
RESULTS
Brain Derived Neurotrophic Factor and Heterozygous Knockout
To confirm the animals used in our experiments had the 7 base pair deletion within
the BDNF gene a Western Blot was run. To verify this deletion occurred the heterozygous
BDNF knock-down (BDNF KD) was compared to naïve Wild Type (WT) animals, to
assess possible functional deficits. Figure 4.1 confirms that both the pro- and mature
forms of BDNF were present in the hippocampal tissue collected post euthanasia for both
male and female rodents. Western Blot results are shown in Figure 4.1A and 4.1B, and
statistical quantification for the blots is presented in the bar graph of Figure 4.1C. The
data was normalized by comparing the heterozygous BDNF knock-down (KD) (BDNF +/-)
protein expression to naïve Wild Type (WT) animals (no genetic modification). Figure 4.1
displays that the BDNF protein levels in the mutant strain are knock-down in both male
and female rodent hippocampi. Verification through statistical analysis, revealed in Table
4.1A and 4.1B, yielded a reduction of pro-BDNF in males that was significant (p<
0.001533). However, the decrease of pro-BDNF in the KD females was not significant (p
< 0.027786). The mature form of BDNF was confirmed through statistical analysis (Table
4.1B) and reported that there was a loss across both sexes, after the knock-down of the
BDNF protein.
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Figure 4.1. Western blot analysis confirmed BDNF heterozygosity. Tissue samples were collected from
the hippocampus of adult BDNF KD and WT rats, both males and females. (A, B) Western blot images of
BDNF expression in the female and male hippocampus show visual reductions in BDNF in the mutant (KD)
rats, as compared to WT controls. (C) Quantification of blots indicates reductions in BDNF in both male and
female KD rats. (*, p < 0.05). Formatting of results figure was adapted from (Mitchell, B. A., 2019).
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Table 4.1. Statistical Analysis for pro-BDNF.
Gender

Significance

P-Value

Mean of WT

Mean of KD

T ratio

df

Female
Male

No
Yes

0.027786
0.001533

0.9020
1.034

0.6025
0.4950

2.768
5.019

7
7

Adjusted
P value*
0.055572
0.003065

Note: * = Adjusted using Bonferroni-Dunn method.

Table 4.2. Statistical Analysis for Mature BDNF.
Mean of
Gender Significance P-Value
WT
Female
Yes
0.013222
0.6880
Male
Yes
0.003192
1.024
Note: * = Adjusted using Bonferroni-Dunn method.
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Mean of
KD
0.4000
0.4725

T ratio

df

Adjusted P value*

3.294
4.391

7
7

0.026443
0.006384

Loss of BDNF and the Inflammasome Pathway - NLRP3
To understand the role of BDNF loss and how it affects inflammation in the central
nervous system, we examined the effects of BDNF loss on Nod-like Receptor Family
Pyrin Domain Containing 3 protein (NLRP3) activation and expression in the rodent
hippocampus of both male and female animals. Western blot analysis for the NLRP3
protein was performed. The representative immunoblots are shown in Figure 4.2A and
4.2B and quantification of the western blots is shown in Figure 4.2C. In summary, Figure
4.2 indicates that the NLRP3 protein showed a visual increase in expression in the BDNF
KD males as compared to WT males. No changes were observed in the female brain
after BDNF KD. The statistical analyses are shown in table (Table 4.3).
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Figure 4.2. NLRP3 did not differ across sex-matched groups. The tissue samples were collected from
the hippocampus of adult female and male BDNF KD and WT rats. (A) Western blot images of NLRP3
protein expression in female hippocampus samples show a slight visual decrease in the KD rats, as
compared to the WT controls. (B) Western blot images of NLRP3 protein expression in male hippocampus
show a visual increase in NLRP3 activation in KD rats, as compared to WT controls. (C) Quantification of
blots did not indicate any significant differences between sex-matched groups. (*, p < 0.05).
Formatting of results figure was adapted from (Mitchell, B. A., 2019).
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Table 4.3. Statistical Analysis for NLRP3.
Gender

Significance

P-Value

Female
Male

No
No

0.433246
0.195669

Mean of
WT
0.2580
0.1360

Note: * = Adjusted using Bonferroni-Dunn method.
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Mean of
KD
0.1725
0.3075

T ratio

df

Adjusted P value*

0.8313
1.430

7
7

0.866492
0.391337

Loss of BDNF and the Inflammasome Pathway – ApoptosisAssociated Speck-Like Protein Containing a CARD (ASC)
To further understand how NLRP3 acts due to loss of BDNF, we needed to
investigate the proteins involved in the NLRP3 pathway. Western blot analysis revealed
that the ASC protein was detected across both sexes in the rat hippocampus. The
representative immunoblots are shown in Figure 4.3A and 4.3B. Quantification of the
western blots is shown in Figure 4.3C. The statistical analyses are shown in table (Table
4.4.).
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Figure 4.3. ASC did not differ across sex-matched groups. The tissue samples were collected from the
hippocampus of adult female and male BDNF KD and WT rats. (A) Western blot images of ASC protein
expression in female hippocampus samples are visually comparable in the KD rats when compared to the
WT controls. (B) Western blot images of ASC protein expression in male hippocampus show a visual
increase in ASC activation in KD rats, as compared to WT controls. (C) Quantification of blots did not
indicate any significant differences between sex-matched groups. (*, p < 0.05).
Formatting of results figure was adapted from (Mitchell, B. A., 2019)
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Table 4.4. Statistical Analysis for ASC.
Gender

Significance

P-Value

Female
Male

No
No

0.053897
0.285696

Mean of
WT
0.02600
0.5740

Note: * = Adjusted using Bonferroni-Dunn method.
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Mean of
KD
0.06500
0.7500

T ratio

df

Adjusted P value*

2.314
1.156

7
7

0.107794
0.571393

Loss of BDNF and the Inflammasome Pathway – Caspase 1
Caspase-1 is a protein that attaches to the NLRP3 complex and is then cleaved if
the inflammasome pathway is activated. The active form of Caspase is the cleaved
caspase which is an enzyme protein that catalyzes a biochemical reaction. Since we were
investigating the NLRP3 pathway it was the next crucial protein to study when examining
inflammasome activation. As depicted in Figure 4.4, Caspase-1 enzyme protein was
detected using western blot analysis and the representative immunoblots are shown in
Figure 4.4 A and 4.4 B. Quantification of the western blots is shown in Figure 4.4 C. In
summary, Figure 4.4 indicates that the enzyme protein levels of Caspase-1 in the female
rodent hippocampus show a decrease in Caspase-1 activation from the BDNF KD to the
WT, however, quantification revealed this decrease is not statistically significant Table
(4.5.). In the male rodent hippocampus, there was a significant increase in Caspase-1
activation in the BDNF KD when compared to the WT. This further confirms in relation to
the above results that the inflammasome pathway is being activated primarily in the male
brain following BDNF loss.
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Figure 4.4. Caspase1 activation was increased in BDNF KD males. Tissue samples were collected from
the hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of
Caspase1 protein expression in female hippocampus show a decrease of Caspase-1 activation from the
WT controls to the BDNF KD rats. (B) Western blot images of Caspase1 protein expression in male
hippocampus show a visual increase in the KD rats, as compared to WT controls. (C) Quantification of
immunoblots showed a significant increase in Caspase1 protein in the knock-down males. The difference
between female groups is not statistically significant. (*, p < 0.05).
This formatting of results figure was adapted from (Mitchell, B. A., 2019)
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Table 4.5. Statistical Analysis for Caspase-1.
Mean of
Gender Significance P-Value
WT
Female
No
0.579414
0.7620
Male
Yes
0.012790
0.4480
Note: * = Adjusted using Bonferroni-Dunn method.
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Mean of
KD
0.5650
0.8600

T ratio

df

Adjusted P value*

0.5811
3.502

7
6

>0.999999
0.025580

Loss of BDNF and the Inflammasome Pathway – Interleukin-1 Beta
(IL1-β)
Interleukin-1 beta (IL1-β) is an active proinflammatory cytokine that once
activated is released outside of the cells to interact with its receptors and activate the
complex inflammatory cascade. We examined the effects of BDNF KD on IL1βactivation in the rodent hippocampus of both females and males. As depicted in Figure
4.5 IL1-β protein was detected using western blot analysis and the representative
immunoblots are shown in Figure 4.5 A and 4.5 B. Quantification of the western blots is
shown in Figure 4.5 C. The statistical analyses are shown in table (Table 4.6.).
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Figure 4.5. IL1-Beta did not differ across sex-matched groups. The tissue samples were collected from
the hippocampus of adult female and male BDNF KD and WT rats. (A) Western blot images of IL1-Beta
protein expression in female hippocampus samples are visually comparable in the KD rats when compared
to the WT controls. (B) Western blot images of IL1-Beta protein expression in male hippocampus show are
visually comparable in IL1-Beta activation in KD rats, as compared to WT controls. (C) Quantification of
blots did not indicate any significant differences between sex-matched groups. (*, p < 0.05).
Formatting of results figure was adapted from (Mitchell, B. A., 2019)
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Table 4.6. Statistical Analysis for IL1-Beta.
Gender

Significance

P-Value

Female
Male

No
No

0.423692
0.194904

Mean of
WT
0.1180
0.9140

Note: * = Adjusted using Bonferroni-Dunn method.
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Mean of
KD
0.07750
1.310

T ratio

df

Adjusted P value*

0.8495
1.433

7
7

0.847384
0.389808

Thioredoxin-Interacting Protein (TXNIP)
Thioredoxin-interacting protein (TXNIP) is a marker known to act as an oxidative
stress mediator by suppressing thioredoxin activity. We examined the effects of BDNF
KD on TXNIP protein expression in male and female rodents. As seen in Figure 4.6 the
TXNIP protein expression was detected using western blot analysis and representative
immunoblots are shown in Figure 4.6 A and 4.6B. Quantification of the western blots is
shown in Figure 4.6C. In summary, Figure 4.6 indicates that the levels of TXNIP protein
visually shown a slight decrease in the BDNF KD females when compared to the WT
females, however, quantification revealed that the difference is not statistically significant.
In the males a visual increase is seen for TXNIP activation and when quantified revealed
that there is a significant increase in TXNIP activation in BDNF KD males when compared
to WT rats. These results suggest that BDNF loss leads to increased oxidative stress in
the male hippocampus but not the female. The statistical analyses are shown in table
(Table 4.7).
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Figure 4.6. TXNIP was increased in BDNF KD males. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of TXNIP
protein expression in female hippocampus samples are comparable to the KD rats, as compared to WT
controls. (B) Western blot images of TXNIP protein expression in male hippocampus show a visual increase
in the KD rats, as compared to WT controls. (C) Quantification of immunoblots showed a significant increase
in TXNIP protein in the knock-down males. The difference between female groups is not statistically
significant. (*, p < 0.05).
This formatting of results figure was adapted from (Mitchell, B. A., 2019)
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Table 4.7. Statistical Analysis for TXNIP.
Gender

Significance

P-Value

Female
Male

No
Yes

0.778769
0.011208

Mean of
WT
2.223
0.9725

Note: * = Adjusted using Bonferroni-Dunn method.

45

Mean of
KD
2.095
1.733

T ratio

df

Adjusted P value*

0.2965
3.612

5
6

>0.999999
0.022416

Ionized Calcium Binding Adaptor Molecule1 (IBA1)
Ionized calcium binding adaptor molecule 1 (Iba1) is a protein marker that is
specific for microglia/macrophages calcium-binding protein. This marker is widely used
to indicate immune system activity. We tested the effects of BDNF KD on Iba1
activation in the hippocampus of both male and female rodents. As depicted in Figure
4.7 IL1-Beta protein was detected using western blot analysis and the representative
immunoblots are shown in Figure 4.7 A and 4.7 B. Quantification of the western blots is
shown in Figure 4.7 C. In summary, Figure 4.7 indicates that no significant changes
were observed in microglia activation of male brains. Iba1 was decreased in BDNF KD
females, this suggests that a full-blown inflammatory cascade is not triggered at basal
level after BDNF loss, but the male brain remains primed for inflammation via activation
of the NLRP3 inflammasome pathway, even despite BDNF knockdown. The statistical
analyses are shown in table (Table 4.8.)
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Figure 4. 7. Iba1 was decreased in BDNF KD females. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of Iba1
protein expression in female hippocampus samples show a visual decrease comparable to the KD rats, as
compared to WT controls. (B) Western blot images of Iba1 protein expression in male hippocampus show
a visual increase in the KD rats, as compared to WT controls. (C) Quantification of immunoblots showed a
significant increase in Iba1 protein in the knock-down females. The difference between male groups is not
statistically significant. (*, p < 0.05). Formatting of results figure was adapted from (Mitchell, B. A., 2019)
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Table 4.8. Statistical Analysis for Iba1.
0Gender

Significance

P-Value

Female
Male

Yes
No

0.000449
0.581003

Mean of
WT
1.193
1.070

Note: * = Adjusted using Bonferroni-Dunn method.
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Mean of
KD
0.4350
0.9025

T ratio

df

Adjusted P value*

6.925
0.5832

6
6

0.000898
>0.999999

Glial Fibrillary Acidic Protein (GFAP)
Glial fibrillary acidic protein (GFAP), is a protein marker that is expressed by
astrocytes in the central nervous system (CNS). We looked for changes in GFAP
expression in the hippocampus of both male and female rodents. As depicted in Figure
4.7 GFAP protein was detected using western blot analysis and the representative
immunoblots are shown in Figure 4.7 A and 4.7 B. Quantification of the western blots is
shown in Figure 4.7 C. In summary, Figure 4.7 indicates that no significant changes
were observed in astrocyte activation for either male or female brains. The statistical
analyses are shown in table (Table 4.9.).
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Figure 4.7. GFAP did not differ across sex-matched groups. The tissue samples were collected from
the hippocampus of adult female and male BDNF KD and WT rats. (A) Western blot images of GFAP
protein expression in female hippocampus samples are visually comparable in the KD rats when compared
to the WT controls. (B) Western blot images of GFAP protein expression in male hippocampus show are
visually comparable in GFAP activation in KD rats, as compared to WT controls. (C) Quantification of blots
did not indicate any significant differences between sex-matched groups. (*, p < 0.05). Formatting of results
figure was adapted from (Mitchell, B. A., 2019)
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Table 4.9 Statistical Analysis of GFAP
Gender

Significance

P-Value

Female
Male

No
No

0.114220
0.548744

Mean of
WT
0.4820
0.6340

Note: * = Adjusted using Bonferroni-Dunn method.
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Mean of
KD
1.123
0.8875

T ratio

df

Adjusted P value*

1.804
0.6299

7
7

0.228439
>0.999999

CHAPTER FIVE
DISCUSSION AND CONCLUSIONS
Discussion
As mentioned previously, we hypothesize that BDNF heterozygous rats will have
altered protein levels of inflammatory markers due to reduction of BDNF expression, and
that this may occur in a sex specific manner. We tested this hypothesis through the
examination of inflammation within the Central Nervous System (CNS), specifically
through examining the NLRP3 inflammasome pathway. We verified this hypothesis by
using sex matched male and female groups comprised of BDNF +/- KD and WT rats.
Our first aim was to understand the basal relationship between BDNF and how its
neuronal functioning affects neuroinflammatory pathways. In accordance with our
hypothesis our study conveys that: BDNF loss changed the protein expression levels of
NLRP3, ASC, Caspase-1, and IL1-β. Our second aim was to determine if sex-differences
play a role in BDNF regulation and neuroinflammation. Our findings indicated that all four
of these inflammasome markers showed a pattern of increase only in the male
hippocampi (HPC) and not in the females after BDNF KD. These results lead us to believe
that the male brain primes for inflammation under reduced levels of BDNF.
Additionally, we found an increase in oxidative stress (TXNIP) was observed in
males but not in female rats after BDNF loss. These results indicate that increased
inflammation after BDNF reduction could be mediated via increased oxidative stress.
Protein expression studies of microglia specific marker, Iba1, and astrocyte specific
marker, GFAP, showed no significant changes after BDNF loss. These results compel us
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to believe that BDNF reduction leads to priming of the inflammation in the brain and not
a full-blown inflammatory state. This is observed in a sex specific manner, with effects
seen only in the male HPC. We further hypothesize that due to a pre-existing BDNF loss
and primed inflammation, the brain will have a worsened outcome after any neuronal
insult. Parallel studies in our lab have found that estrogen in reproductive-aged females
has neuroprotective effects post-BDNF loss (Mitchell, B. A., 2019), which was
corroborated in our study (i.e., males had priming of inflammation over females).Future
endeavors should target more effective treatment options for neurological and psychiatric
diseases using BDNF as an early detection biomarker for neuroinflammation.
Limitations of the Study
Future directions for this research to have a higher impact would be to increase
the sample size to increase statistical power. Further studies are needed to confirm that
males are the only sex experiencing the priming of the NLRP3 inflammasome pathway.
Additional parallel studies could investigate the effects of BDNF loss in other limbic
structures: striatum, cortex, thalamus, and brainstem. This investigation has deduced that
BDNF loss primes the brain to inflammasome activation, and likely more so in male
animals. Consequently, we suggest that further investigation is needed on the pattern
and timing of inflammation activation resulting in sex dependent changes of neurotrophin
expression. We must acknowledge that sex dependent factors are key components of
neurophysiology and will vary accordingly. The trends witnessed within our study could
be explained by the priming of inflammation due to oxidative stress and in males because
of the absence of E2 within the CNS (Thakkar, Wang, Wang, Vadlamudi, & Brann, 2018).
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However, this investigation is limited to the HPC. Future objectives for this study will
include analysis of additional limbic structures, inflammasome, and glial cell protein
markers. Additional studies on disease models and aged animals may be beneficial.

Conclusions
This study provides meaningful information for pre-clinical animal models, with
crucial translational value. We have concluded that when BDNF is reduced, a cascade of
neurotrophic downstream signaling is inhibited or disrupted. BDNF in both its pro and
mature forms is essential for healthy brain function. This investigation has illustrated that
BDNF loss activates the NLRP3 inflammasome pathway, setting forth a cascade of
inflammation activation, increasing oxidative stress and culminating in an immune
response from glial cells in the CNS. We also highlighted that the male and female brain
handle BDNF loss differently: reproductive aged females do not experience the same
priming for inflammation that males experience. This study was novel because BDNF has
not been extensively assessed in healthy non-disease model brains, not have sex
differences have been examined. We believe this information will aid researchers in their
future endeavors to create targeted treatment therapies for neurodegenerative and
psychiatric diseases.
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